Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
Open Access
- 7 May 2019
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (07), 1084-1093
- https://doi.org/10.1055/s-0039-1688687
Abstract
Emicizumab bridges activated factor IX (FIX) and FX to restore the tenase function mediated by activated FVIII (FVIIIa), which is deficient in people with haemophilia A (PwHA). Unlike FVIII, emicizumab does not require activation to function; thus, in coagulation assays, the behavior of emicizumab may differ from that of FVIII. The objective of this study was to assess the effect of emicizumab on coagulation assays, including potential interference behavior that may produce inaccurate or misleading results. A variety of clotting-based, amidolytic/chromogenic, latex particle-enhanced turbidometric, and enzyme-linked immunosorbent methods were investigated. As expected based on its pharmacologic mechanism of action, emicizumab exhibited strong activity on the activated partial thromboplastin time (aPTT), which resulted in interference with several aPTT-based assays, most importantly the one-stage FVIII activity assay; these assays are not recommended for PwHA receiving emicizumab therapy. Pharmacodynamic activity of emicizumab, as measured by FVIII chromogenic assays, was species-dependent due to the binding specificity of the drug antibody. Outside of FVIII assays, emicizumab did not interfere with assays based on immunologic or chromogenic principles, nor with clotting assays based on nonintrinsic pathway activators, thus offering alternative choices where aPTT-based assays might otherwise be used. The observed interferences are in line with the unique mechanism of action of emicizumab. Potential interferences should be taken into account in the selection of coagulation assays and interpretation of coagulation assay test results for PwHA receiving emicizumab therapy. Investigations were performed at Menal GmbH, Emmendingen, Germany.Keywords
This publication has 29 references indexed in Scilit:
- Current laboratory practices in the diagnosis and management of haemophilia: a global assessmentHaemophilia, 2015
- Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research StudyJournal of Thrombosis and Haemostasis, 2013
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Effects of telavancin on coagulation test resultsInternational Journal of Clinical Practice, 2011
- Factor VIII Structure and FunctionInternational Journal of Hematology, 2006
- Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assaysJournal of Thrombosis and Haemostasis, 2004
- Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial FibrillationThe New England Journal of Medicine, 2003
- Risk Factors for Intracranial Hemorrhage in Outpatients Taking WarfarinAnnals of Internal Medicine, 1994